Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 241, pseudogene (RN7SL241P) is a non-coding pseudogene derived from the *functional* 7SL RNA gene. The canonical 7SL RNA serves as a critical component of the signal recognition particle (SRP), which guides ribosome-nascent protein complexes to the endoplasmic reticulum for protein translocation and secretion[1][4]. Unlike its functional counterpart, RN7SL241P is classified as a pseudogene: it is a truncated, nonfunctional sequence resulting from the retrotransposition of 7SL RNA back into the genome, lacking essential features for canonical molecular activity[7]. The majority of the several hundred 7SL RNA-like copies in the human genome are pseudogenes with high sequence variability and diverse truncated structures, and no established physiological or pathological role has been reported for this specific pseudogene[7]. There is extensive evidence that *some* pseudogenes in general can regulate gene expression by acting as competing endogenous RNAs (ceRNAs) or miRNA decoys, but no such mechanism or role has been specifically described for RN7SL241P[2][5]. Key notes: - This molecule is not a therapeutic target (e.g., receptor, enzyme, transporter). - RN7SL241P is an annotated pseudogene with no evidence of protein-coding function, druggability, or direct clinical utility. - There is no known use of this pseudogene as a biomarker, no documented interaction with drugs, and no associated mechanism of action or safety issues. Conclusion: RN7SL241P refers to a nonfunctional pseudogene derived from the 7SL RNA gene, with no direct biological, disease, or therapeutic significance based on current scientific knowledge[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 241, pseudogene (RN7SL241P).